RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Amvuttra Survey Suggests 2Q Beat'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $330.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
